BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
1.990
-0.030 (-1.49%)
At close: Oct 30, 2026, 4:00 PM EDT
1.950
-0.040 (-2.01%)
After-hours: Oct 30, 2026, 4:10 PM EDT
BioLineRx Revenue
BioLineRx had revenue of $294.00K in the quarter ending June 30, 2026, a decrease of -3.29%. This brings the company's total for the last twelve months to $1.39M, down -91.93% year-over-year. In the year 2025, BioLineRx had annual revenue of $1.18M, down -95.92%.
Revenue (ttm)
$1.39M
Revenue Growth
-91.93%
P/S Ratio
6.83
Revenue / Employee
$58,000
Employees
24
Market Cap
9.50M
Revenue by Geography
- China 14.96M 51.7%
- U.s. 13.98M 48.3%
Fiscal year ended Dec 31, 2024 See the full BioLineRx breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18M | -27.76M | -95.92% |
| Dec 31, 2024 | 28.94M | 24.14M | 502.92% |
| Dec 31, 2023 | 4.80M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
BLRX News
- 9 days ago - BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 - PRNewsWire
- 24 days ago - BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day - PRNewsWire
- 5 weeks ago - BioLineRx files to sell 2.02M American Depositary Shares for holders - TheFly
- 5 weeks ago - BioLineRx Registration statement: Registration filing - Filings
- 7 weeks ago - BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - PRNewsWire
- 2 months ago - BioLineRx Releases Q2 2026 Financial Results - AlphaStreet
- 2 months ago - BioLineRx Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - BioLineRx Earnings release: Q2 2026 - Filings